.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Chubb
Cantor Fitzgerald
AstraZeneca
McKesson
Medtronic
Cipla
Teva
Cerilliant
Citi

Generated: July 22, 2017

DrugPatentWatch Database Preview

Merck And Co Inc Company Profile

« Back to Dashboard

What is the competitive landscape for MERCK AND CO INC, and when can generic versions of MERCK AND CO INC drugs launch?

MERCK AND CO INC has two approved drugs.

There is one US patent protecting MERCK AND CO INC drugs on MERCK AND CO INC drugs in the past three years.

There are thirty-six patent family members on MERCK AND CO INC drugs in twenty-seven countries.

Summary for Applicant: Merck And Co Inc

Patents:1
Tradenames:2
Ingredients:2
NDAs:2
Drug Master File Entries: (click here to view)13
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck And Co Inc
FOSAMAX
alendronate sodium
TABLET;ORAL020560-005Oct 20, 2000ABRXYesYes► Subscribe► Subscribe
Merck And Co Inc
EMEND
fosaprepitant dimeglumine
POWDER;INTRAVENOUS022023-002Nov 12, 2010APRXYesYes► Subscribe► Subscribe
Merck And Co Inc
EMEND
fosaprepitant dimeglumine
POWDER;INTRAVENOUS022023-002Nov 12, 2010APRXYesYes5,691,336► SubscribeYY ► Subscribe
Merck And Co Inc
FOSAMAX
alendronate sodium
TABLET;ORAL020560-003Apr 25, 1997DISCNYesNo► Subscribe► Subscribe
Merck And Co Inc
FOSAMAX
alendronate sodium
TABLET;ORAL020560-004Oct 20, 2000DISCNYesNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Merck And Co Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck And Co Inc
FOSAMAX
alendronate sodium
TABLET;ORAL020560-002Sep 29, 19955,358,941*PED► Subscribe
Merck And Co Inc
FOSAMAX
alendronate sodium
TABLET;ORAL020560-001Sep 29, 19954,621,077*PED► Subscribe
Merck And Co Inc
FOSAMAX
alendronate sodium
TABLET;ORAL020560-005Oct 20, 20005,681,590*PED► Subscribe
Merck And Co Inc
FOSAMAX
alendronate sodium
TABLET;ORAL020560-004Oct 20, 20005,681,590*PED► Subscribe
Merck And Co Inc
FOSAMAX
alendronate sodium
TABLET;ORAL020560-002Sep 29, 19955,804,570► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for MERCK AND CO INC drugs

Drugname Dosage Strength Tradename Submissiondate
aprepitant
for Oral Suspension125 mg/Kit
EMEND
11/23/2016
fosaprepitant dimeglumine
Injection115 mg/vial
EMEND
1/25/2012
fosaprepitant dimeglumine
Injection150 mg/vial
EMEND
1/25/2012
aprepitant
Capsule40 mg, 80 mg and 125 mg
EMEND
11/3/2008
alendronate sodium
Oral Solution70 mg/75 mL
FOSAMAX
9/7/2007

Non-Orange Book Patents for Merck And Co Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,512,570 Treatment of emesis with morpholine tachykinin receptor antagonists► Subscribe
5,780,467 Morpholine compounds are prodrugs useful as tachykinin receptor antagonists► Subscribe
5,716,942 Treatment of migraine with morpholine tachykinin receptor antagonists► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Merck And Co Inc Drugs

Country Document Number Estimated Expiration
Finland963450► Subscribe
Latvia11688► Subscribe
Austria227722► Subscribe
Bulgaria100798► Subscribe
Czech Republic288241► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Merck And Co Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB08/021United Kingdom► SubscribePRODUCT NAME: FOSAPREPITANT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE BIS(N-METHYL-D-GLUCAMINE)SALT; REGISTERED: UK EU/1/07/437/001 20080111; UK EU/1/07/437/002 20080111
C0019France► SubscribePRODUCT NAME: FOSAPREPITANT DIMEGLUMINE; REGISTRATION NO/DATE: EU/1/07/437/001 20080111
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Medtronic
Federal Trade Commission
Citi
Harvard Business School
US Department of Justice
Chinese Patent Office
McKesson
Queensland Health
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot